6,8-dibromo-5-methylimidazo[1,2-a]pyridine | 217435-66-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6,8-dibromo-5-methylimidazo[1,2-a]pyridine
• CAS: 217435-66-0
• 化学式: C₈H₆Br₂N₂
• 分子量: 289.957
• InChiKey: ZRRIFCUJGZUPCH-UHFFFAOYSA-N

物化性质

• 密度：
  2.01±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6,8-dibromo-5-methylimidazo[1,2-a]pyridine 在 sodium acetate 、 溶剂黄146 作用下， 反应 2.0h， 生成 3-(Benzylsulfanylmethyl)-6,8-dibromo-5-methyl-imidazo[1,2-a]pyridine
  参考文献：
  名称：

  Synthesis of Imidazo[1,2-a]pyridines as Antiviral Agents

  摘要：

  The synthesis of original imidazo[1,2-a]pyridines bearing a thioether side chain at the 3 position and their antiviral activity are reported. From the synthesized compounds, 4, 15, and 21 were highly active against human cytomegalovirus with a therapeutic index superior to 150. These compounds also showed pronounced activity against varicella-zoster virus. Their structure-activity relationship is discussed.

  DOI：

  10.1021/jm981051y
• 作为产物：
  描述：

  紫藤提取物 、 溴乙醛 以 乙醇 为溶剂， 反应 4.0h， 以92%的产率得到6,8-dibromo-5-methylimidazo[1,2-a]pyridine
  参考文献：
  名称：

  Synthesis of Imidazo[1,2-a]pyridines as Antiviral Agents

  摘要：

  The synthesis of original imidazo[1,2-a]pyridines bearing a thioether side chain at the 3 position and their antiviral activity are reported. From the synthesized compounds, 4, 15, and 21 were highly active against human cytomegalovirus with a therapeutic index superior to 150. These compounds also showed pronounced activity against varicella-zoster virus. Their structure-activity relationship is discussed.

  DOI：

  10.1021/jm981051y

文献信息

• [EN] IMIDAZOPYRIDINES SYK INHIBITORS<br/>[FR] INHIBITEURS DE SYK À BASE D'IMIDAZOPYRIDINES
  申请人：GILEAD SCIENCES INC

  公开号：WO2011112995A1

  公开（公告）日：2011-09-15

  Certain imidazopyridines (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

  本文提供了某些咪唑吡啶(I)及其药物组合物。提供了治疗对Syk活性抑制敏感的患者患有某些疾病和疾病的方法，包括向这些患者施用至少一种有效减轻疾病或疾病症状的化学实体。还提供了一种确定样本中Syk激酶存在或不存在的方法。
• IMIDAZOPYRIDINES SYK INHIBITORS
  申请人：Blomgren Peter A.

  公开号：US20140148430A1

  公开（公告）日：2014-05-29

  Certain imidazopyridines (I) and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

  本文提供了某些咪唑吡啶(I)及其药物组合物。提供了治疗对Syk活性抑制敏感的患者患有某些疾病和疾病的方法，包括向这些患者施用至少一种有效减轻疾病或疾病症状的化学实体。还提供了一种确定样本中Syk激酶存在或不存在的方法。
• [EN] OXO-NITROGEN RING DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF<br/>[FR] RÉGULATEUR DE DÉRIVÉ À CYCLE OXO-AZOTE, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION<br/>[ZH] 氧代氮环类衍生物调节剂、其制备方法和应用
  申请人：SHANGHAI HANSOH BIOMEDICAL CO LTD

  公开号：WO2022121914A1

  公开（公告）日：2022-06-16

  一种氧代氮环类衍生物调节剂、其制备方法和应用，涉及氧代氮环类衍生物的调节剂、其制备方法和应用。特别地，涉及通式(I)所示的化合物、其制备方法及含有该化合物的药物组合物，及其作为调节剂在制备治疗癌症相关药物中的应用，其中通式(I)中的各取代基与说明书中的定义相同。
• Imidazopyridines Syk inhibitors
  申请人：Gilead Connecticut, Inc.

  公开号：US10092583B2

  公开（公告）日：2018-10-09

  Certain imidazopyridines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

  本文提供了某些咪唑吡啶及其药物组合物。 本文还提供了治疗对抑制 Syk 活性有反应的某些疾病和失调患者的方法，其中包括向这些患者施用一定量的至少一种化学实体，以有效减少疾病或失调的体征或症状。 还提供了确定样品中是否存在 Syk 激酶的方法。
• US9562056B2
  申请人：——

  公开号：US9562056B2

  公开（公告）日：2017-02-07